Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

171

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Lung
Extensive Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: Ponatinib

Sponsor

University of Colorado, Denver

Collaborators

[object Object]